Keynote B61 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Focusing on the KEYNOTE-B61 trial evaluating lenvatinib plus pembrolizumab in the first line, a panel of medical oncologists react to clinical trial data on combination regimens in non–clear cell renal cell carcinoma.

Advanced renal cell carcinomaLenvatinib plus pembrolizumabClear cellRenal cell carcinomaAdvanced rccNon clear cell rccNon clear cell renal carcinomaKeynote b61